Elimination of IDH1 in human acute promyelocytic leukemia (APL) resulted in a phenotype similar to that observed with griseofulvin B (GCN B) treatment, one of the most common active secondary metabolites with potent antitumor activities. Here, IDH1 is linked to acute promyelocytic leukemia.